picolinic acid has been researched along with Insulin Resistance in 30 studies
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Smoking promotes insulin resistance and other features - excepting hypertension - of the insulin resistance syndrome; these effects appear to reflect chronic nicotine exposure." | 3.73 | Chromium picolinate may favorably influence the vascular risk associated with smoking by combating cortisol-induced insulin resistance. ( McCarty, MF, 2005) |
| " Peripheral insulin resistance, which usually responds to a very-low-fat diet, aerobic exercise training, and appropriate weight loss, can also treated with high-dose chromium picolinate, high-dose vitamin E, magnesium, soluble fiber, and possibly taurine; these measures appear likely to correct the diabetes-associated metabolic derangements of vascular smooth muscle, and thus lessen risk for macrovascular disease." | 3.69 | Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications. ( McCarty, MF, 1997) |
| "Insulin sensitivity was negatively correlated to soleus and tibialis muscle intramyocellular lipids and intrahepatic lipid content." | 2.75 | Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. ( Anderson, RA; Cefalu, WT; Levitan, L; Martin, CK; Martin, JM; Newcomer, B; Pinsonat, P; Qin, J; Rood, J; Sereda, O; Wang, ZQ; Zhang, XH, 2010) |
| "Metabolic syndrome is defined by a cluster of cardiovascular disease risk factors that are associated with insulin resistance." | 2.47 | Alternative and complementary treatments for metabolic syndrome. ( Power, M; Pratley, R, 2011) |
| "Chromium (Cr) has been shown to potentiate insulin functioning and is thereby helpful in reducing the risk of these metabolic disorders." | 1.91 | Dietary Chromium Picolinate Supplementation Improves Glucose Utilization in Transition Calf by Ameliorating Insulin Response. ( Khare, S; Kumar, A; Kumar, M; Kumar, V; Kushwaha, R; Shukla, PK; Singh, SK; Singh, Y; Vaswani, S; Yadav, RS, 2023) |
| "Obesity is a prevalent disorder characterized as marked insulin resistance and low grade inflammation." | 1.37 | Submandibular gland and caries susceptibility in the obese Zucker rat. ( Abdelsayed, R; El-Marakby, A; El-Salanty, M; Liu, JY; Mozaffari, MS; Wimborne, H; Zakhary, I, 2011) |
| "Treatment with chromium picolinate produced a significant decrease in elevated cholesterol and triglyceride levels in both types of diabetic rats." | 1.32 | Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitus. ( Dhalla, NS; Goyal, RK; Sharma, G; Shindea, UA; Xu, YJ, 2004) |
| "To evaluate whether CrPic may aid in treatment of the insulin resistance syndrome, we assessed its effects in JCR:LA-corpulent rats, a model of this syndrome." | 1.31 | Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. ( Baldor, LC; Cefalu, WT; Russell, JC; Wang, ZQ; Zhang, XH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 17 (56.67) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Khare, S | 1 |
| Kumar, M | 1 |
| Kumar, V | 1 |
| Kushwaha, R | 1 |
| Vaswani, S | 1 |
| Kumar, A | 1 |
| Yadav, RS | 1 |
| Singh, SK | 1 |
| Singh, Y | 1 |
| Shukla, PK | 1 |
| Moradi, F | 1 |
| Kooshki, F | 1 |
| Nokhostin, F | 1 |
| Khoshbaten, M | 1 |
| Bazyar, H | 1 |
| Pourghassem Gargari, B | 1 |
| Jamilian, M | 1 |
| Asemi, Z | 1 |
| Ashoush, S | 1 |
| Abou-Gamrah, A | 1 |
| Bayoumy, H | 1 |
| Othman, N | 1 |
| Sala, M | 1 |
| Breithaupt, L | 1 |
| Bulik, CM | 1 |
| Hamer, RM | 1 |
| La Via, MC | 1 |
| Brownley, KA | 1 |
| Horvath, EM | 2 |
| Tackett, L | 2 |
| Elmendorf, JS | 2 |
| Wang, YQ | 2 |
| Yao, MH | 2 |
| Dong, Y | 1 |
| Cefalu, WT | 3 |
| Rood, J | 1 |
| Pinsonat, P | 1 |
| Qin, J | 1 |
| Sereda, O | 1 |
| Levitan, L | 1 |
| Anderson, RA | 1 |
| Zhang, XH | 3 |
| Martin, JM | 1 |
| Martin, CK | 1 |
| Wang, ZQ | 3 |
| Newcomer, B | 1 |
| Aghdassi, E | 1 |
| Arendt, BM | 1 |
| Salit, IE | 1 |
| Mohammed, SS | 1 |
| Jalali, P | 1 |
| Bondar, H | 1 |
| Allard, JP | 1 |
| Mozaffari, MS | 1 |
| Abdelsayed, R | 1 |
| Zakhary, I | 1 |
| El-Salanty, M | 1 |
| Liu, JY | 1 |
| Wimborne, H | 1 |
| El-Marakby, A | 1 |
| Power, M | 1 |
| Pratley, R | 1 |
| Jiajun, Y | 1 |
| Aiyun, H | 1 |
| Shanshan, Z | 1 |
| Minhong, Z | 1 |
| Kim, DS | 2 |
| Kim, TW | 2 |
| Kang, JS | 2 |
| Shindea, UA | 1 |
| Sharma, G | 1 |
| Xu, YJ | 1 |
| Dhalla, NS | 1 |
| Goyal, RK | 1 |
| Ravina, A | 1 |
| McCarty, MF | 4 |
| Docherty, JP | 1 |
| Sack, DA | 1 |
| Roffman, M | 1 |
| Finch, M | 1 |
| Komorowski, JR | 1 |
| Lucidi, RS | 1 |
| Thyer, AC | 1 |
| Easton, CA | 1 |
| Holden, AE | 1 |
| Schenken, RS | 1 |
| Brzyski, RG | 1 |
| Russell, JC | 3 |
| Hulver, M | 1 |
| Lydic, ML | 1 |
| McNurlan, M | 1 |
| Bembo, S | 1 |
| Mitchell, L | 1 |
| Komaroff, E | 1 |
| Gelato, M | 1 |
| Trumbo, PR | 1 |
| Ellwood, KC | 1 |
| Proctor, SD | 1 |
| Kelly, SE | 1 |
| Stanhope, KL | 1 |
| Havel, PJ | 1 |
| McCarthy, AM | 1 |
| Raman, P | 1 |
| Brozinick, JT | 1 |
| Feiner, JJ | 1 |
| McNurlan, MA | 1 |
| Ferris, RE | 1 |
| Mynarcik, DC | 1 |
| Gelato, MC | 1 |
| Park, IK | 1 |
| Om, AS | 1 |
| Baldor, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chromium and Insulin Action[NCT00398853] | Phase 4 | 100 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| The Effects of Chromium Supplementation on Glucose and Lipid Metabolism in Patients With HIV Infection[NCT00152893] | Phase 2 | 52 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for picolinic acid and Insulin Resistance
| Article | Year |
|---|---|
Alternative and complementary treatments for metabolic syndrome.
Topics: Animals; Cinnamomum zeylanicum; Humans; Insulin Resistance; Metabolic Syndrome; Picolinic Acids; Pla | 2011 |
Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; Evidence-Based Medicine; Food Labelin | 2006 |
10 trials available for picolinic acid and Insulin Resistance
| Article | Year |
|---|---|
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
Topics: Adult; alpha-2-HS-Glycoprotein; Biomarkers; C-Reactive Protein; Dietary Supplements; Double-Blind Me | 2021 |
Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Cholesterol; Cholesterol, VLDL; Dietary Supplements; Double-Blind Method; Fasting; Female; Ho | 2015 |
Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial.
Topics: Adult; Dietary Supplements; Female; Humans; Insulin Resistance; Outcome Assessment, Health Care; Pic | 2016 |
A Double-Blind, Randomized Pilot Trial of Chromium Picolinate for Overweight Individuals with Binge-Eating Disorder: Effects on Glucose Regulation.
Topics: Adult; Binge-Eating Disorder; Blood Glucose; Dose-Response Relationship, Drug; Double-Blind Method; | 2017 |
Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Composition; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2 | 2010 |
In patients with HIV-infection, chromium supplementation improves insulin resistance and other metabolic abnormalities: a randomized, double-blind, placebo controlled trial.
Topics: Blood Chemical Analysis; Body Composition; Body Weight; Diet; Dietary Supplements; Female; HIV; HIV | 2010 |
A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving.
Topics: Adult; Appetite; Depressive Disorder; Dietary Carbohydrates; Double-Blind Method; Female; Humans; Hy | 2005 |
Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Glucose Intolerance; Humans; Insulin Resistance; Iron Chelating Agents; M | 2005 |
Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Insulin Resistance; Iron Chelating Agents; Obesity; Picolini | 2006 |
Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Glucose Clamp Technique; HIV Infections; Human | 2008 |
18 other studies available for picolinic acid and Insulin Resistance
| Article | Year |
|---|---|
Dietary Chromium Picolinate Supplementation Improves Glucose Utilization in Transition Calf by Ameliorating Insulin Response.
Topics: Animal Feed; Animals; Blood Glucose; Cattle; Chromium; Diet; Dietary Supplements; Fatty Acids, Nones | 2023 |
A novel membrane-based anti-diabetic action of atorvastatin.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Atorvastatin; Cell Membrane; Cholesterol; Heptanoic Acids; Hydrox | 2008 |
Effects of chromium picolinate on glucose uptake in insulin-resistant 3T3-L1 adipocytes involve activation of p38 MAPK.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Chromium; Enzyme Activation; Glucose; Glucose Transporter Type 4; | 2009 |
Chromium picolinate inhibits resistin secretion in insulin-resistant 3T3-L1 adipocytes via activation of amp-activated protein kinase.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Ty | 2009 |
Submandibular gland and caries susceptibility in the obese Zucker rat.
Topics: Animals; Dental Caries; Dental Caries Susceptibility; Dietary Supplements; Inflammation Mediators; I | 2011 |
Regulation of organic nucleic acids and serum biochemistry parameters by dietary chromium picolinate supplementation in swine model.
Topics: Animals; Blood; Blood Glucose; Dietary Supplements; Humans; Insulin; Insulin Resistance; Iron Chelat | 2011 |
Chromium picolinate supplementation improves insulin sensitivity in Goto-Kakizaki diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dietary Supplements; Glucose T | 2004 |
Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitus.
Topics: 3T3 Cells; Animals; Animals, Newborn; Area Under Curve; Cell Differentiation; Cholesterol; Chromium; | 2004 |
Initiating insulin in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Picolinic Acids | 2004 |
Chromium picolinate may favorably influence the vascular risk associated with smoking by combating cortisol-induced insulin resistance.
Topics: Adrenocorticotropic Hormone; Animals; Cardiovascular Diseases; Dexamethasone; Dietary Supplements; H | 2005 |
Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats.
Topics: Animals; Glucose; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Muscle, Sk | 2006 |
Synergistic effects of conjugated linoleic acid and chromium picolinate improve vascular function and renal pathophysiology in the insulin-resistant JCR:LA-cp rat.
Topics: Adiponectin; Albuminuria; Animals; Aorta; Body Weight; Diabetic Nephropathies; Dose-Response Relatio | 2007 |
Antidiabetogenic effects of chromium mitigate hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance.
Topics: Animals; Cell Membrane; Cholesterol; Cytoskeleton; Female; Glucose; Glucose Transporter Type 4; Hype | 2008 |
Homologous physiological effects of phenformin and chromium picolinate.
Topics: Adipose Tissue; Aging; Animals; Brain; Humans; Insulin Resistance; Longevity; Neoplasms, Experimenta | 1993 |
Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density.
Topics: Animals; Bone Density; Bone Resorption; Calcium; Collagen; Dehydroepiandrosterone; Dehydroepiandrost | 1995 |
Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications.
Topics: Complementary Therapies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diet, Fat-Restricted; Die | 1997 |
Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body weight in dexamethasone-treated rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Dexamethasone; Dietary Supplements; Glucocorticoid | 2002 |
Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats.
Topics: Administration, Oral; Animals; Area Under Curve; Blood Glucose; Carbohydrate Metabolism; Diabetes Me | 2002 |